Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing Limit of Detection in Clinical Sequencing.

The Journal of molecular diagnostics : JMD - 1 Apr 2021

Starks Elizabeth R, Swanson Lucas, Docking T Roderick, Bosdet Ian, Munro Sarah, Moore Richard A, Karsan Aly

Abstract excerpt

Clinical reporting of solid tumor sequencing requires reliable assessment of the accuracy and reproducibility of each assay. Somatic mutation variant allele fractions may be below 10% in many samples due to sample heterogeneity, tumor clonality, and/or sample degradation in fixatives such as formalin. The toolkits available to the clinical sequencing community for correlating assay design parameters with assay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA
Share to Genomics
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Limit of Detection

Share to Models, Statistical

Share to Neoplasms

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 33486075
DOI: 10.1016/j.jmoldx.2020.12.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing Limit of Detection in Clinical Sequencing.PMID 33486075Read ↗

Impact of Reducing DNA Input on Next-Generation Sequencing Library Complexity and Variant Detection.Semantic proximity Read ↗

Quantifying Somatic Mutation Burden: An Assay Validation Framework and Implementation in SomaticCODECSemantic proximity Read ↗

Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panelSemantic proximity Read ↗

Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel AssaySemantic proximity Read ↗

Validation and benchmarking of targeted panel sequencing for cancer genomic profiling.Semantic proximity Read ↗

Achieving reproducibility and accuracy in cancer mutation detection with whole-genome and whole-exome sequencingSemantic proximity Read ↗

Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.Semantic proximity Read ↗

Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsiesSemantic proximity Read ↗

Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing–Based Oncology AssaysSemantic proximity Read ↗

Optimization of Tumor Dissection Procedures Leads to Measurable Improvement in the Quality of Molecular Testing.Semantic proximity Read ↗

Quantifying sequencing error and effective sequencing depth of liquid biopsy NGS with UMI error correction.Semantic proximity Read ↗

Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.